Literature DB >> 26862115

Detection of an Immunogenic HERV-E Envelope with Selective Expression in Clear Cell Kidney Cancer.

Elena Cherkasova1, Claire Scrivani1, Susan Doh1, Quinn Weisman1, Yoshiyuki Takahashi1, Nanae Harashima1, Hisayuki Yokoyama1, Ramaprasad Srinivasan2, W Marston Linehan2, Michael I Lerman1, Richard W Childs3.   

Abstract

VHL-deficient clear cell renal cell carcinomas (ccRCC), the most common form of kidney cancer, express transcripts derived from the novel human endogenous retrovirus HERV-E (named CT-RCC HERV-E). In this study, we define a transcript encoding the entire envelope gene of HERV-E as expressed selectively in ccRCC tumors, as distinct from normal kidney tissues or other tumor types. Sequence analysis of this envelope transcript revealed long open reading frames encoding putative surface and transmembrane envelope proteins. Retroviral envelopes are known to be capable of eliciting immunity in humans. Accordingly, we found that HLA-A*0201-restricted peptides predicted to be products of the CT-RCC HERV-E envelope transcript-stimulated CD8(+) T cells, which could recognize HLA-A*0201-positive HERV-E-expressing kidney tumor cells. Overall, our results offer evidence of unique HERV-E envelope peptides presented on the surface of ccRCC cells, offering potentially useful tumor-restricted targets for T-cell-based immunotherapy of kidney cancer. Cancer Res; 76(8); 2177-85. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26862115      PMCID: PMC4873424          DOI: 10.1158/0008-5472.CAN-15-3139

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  24 in total

1.  An envelope glycoprotein of the human endogenous retrovirus HERV-W is expressed in the human placenta and fuses cells expressing the type D mammalian retrovirus receptor.

Authors:  J L Blond; D Lavillette; V Cheynet; O Bouton; G Oriol; S Chapel-Fernandes; B Mandrand; F Mallet; F L Cosset
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

2.  Expression of multiple human endogenous retrovirus surface envelope proteins in ovarian cancer.

Authors:  Feng Wang-Johanning; Jinsong Liu; Kiera Rycaj; Miao Huang; Kate Tsai; Daniel G Rosen; Dung-Tsa Chen; Danielle W Lu; Kirstin F Barnhart; Gary L Johanning
Journal:  Int J Cancer       Date:  2007-01-01       Impact factor: 7.396

3.  Endogenous retrovirus sequences as a novel class of tumor-specific antigens: an example of HERV-H env encoding strong CTL epitopes.

Authors:  Christina S Mullins; Michael Linnebacher
Journal:  Cancer Immunol Immunother       Date:  2011-12-21       Impact factor: 6.968

4.  Cytotoxicity of human endogenous retrovirus K-specific T cells toward autologous ovarian cancer cells.

Authors:  Kiera Rycaj; Joshua B Plummer; Bingnan Yin; Ming Li; Jeremy Garza; Laszlo Radvanyi; Lois M Ramondetta; Kevin Lin; Gary L Johanning; Dean G Tang; Feng Wang-Johanning
Journal:  Clin Cancer Res       Date:  2014-11-04       Impact factor: 12.531

Review 5.  Oncogenic transformation by the jaagsiekte sheep retrovirus envelope protein.

Authors:  S-L Liu; A D Miller
Journal:  Oncogene       Date:  2006-08-14       Impact factor: 9.867

6.  Sequence variability, gene structure, and expression of full-length human endogenous retrovirus H.

Authors:  Patric Jern; Göran O Sperber; Göran Ahlsén; Jonas Blomberg
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

7.  Detecting the expression of human endogenous retrovirus E envelope transcripts in human prostate adenocarcinoma.

Authors:  Feng Wang-Johanning; Andra R Frost; Bixi Jian; Ricardo Azerou; Danielle W Lu; Dung-Tsa Chen; Gary L Johanning
Journal:  Cancer       Date:  2003-07-01       Impact factor: 6.860

8.  A human endogenous retroviral sequence encoding an antigen recognized on melanoma by cytolytic T lymphocytes.

Authors:  Francesca Schiavetti; Joëlle Thonnard; Didier Colau; Thierry Boon; Pierre G Coulie
Journal:  Cancer Res       Date:  2002-10-01       Impact factor: 12.701

9.  Identification of Programmed Death Ligand 1-derived Peptides Capable of Inducing Cancer-reactive Cytotoxic T Lymphocytes From HLA-A24+ Patients With Renal Cell Carcinoma.

Authors:  Takafumi Minami; Tomoko Minami; Nobutaka Shimizu; Yutaka Yamamoto; Marco De Velasco; Masahiro Nozawa; Kazuhiro Yoshimura; Nanae Harashima; Mamoru Harada; Hirotsugu Uemura
Journal:  J Immunother       Date:  2015-09       Impact factor: 4.456

10.  The activation of human endogenous retrovirus K (HERV-K) is implicated in melanoma cell malignant transformation.

Authors:  A Serafino; E Balestrieri; P Pierimarchi; C Matteucci; G Moroni; E Oricchio; G Rasi; A Mastino; C Spadafora; E Garaci; P Sinibaldi Vallebona
Journal:  Exp Cell Res       Date:  2009-01-08       Impact factor: 3.905

View more
  43 in total

1.  Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma.

Authors:  Christof C Smith; Kathryn E Beckermann; Dante S Bortone; Aguirre A De Cubas; Lisa M Bixby; Samuel J Lee; Anshuman Panda; Shridar Ganesan; Gyan Bhanot; Eric M Wallen; Matthew I Milowsky; William Y Kim; W Kimryn Rathmell; Ronald Swanstrom; Joel S Parker; Jonathan S Serody; Sara R Selitsky; Benjamin G Vincent
Journal:  J Clin Invest       Date:  2018-10-02       Impact factor: 14.808

Review 2.  CTRL+INSERT: retrotransposons and their contribution to regulation and innovation of the transcriptome.

Authors:  Jonathan Göke; Huck Hui Ng
Journal:  EMBO Rep       Date:  2016-07-11       Impact factor: 8.807

3.  Impact of HLA-G polymorphism on the outcome of allogeneic hematopoietic stem cell transplantation for metastatic renal cell carcinoma.

Authors:  R Crocchiolo; O Ringden; J-O Bay; D Blaise; B Omasic; B Mazzi; C Picard; S Trinca; L Barkholt; J Peccatori; S Gregori; G Amodio; K Fleischhauer; F Ciceri; M Bregni
Journal:  Bone Marrow Transplant       Date:  2017-11-13       Impact factor: 5.483

4.  Epigenetic Therapies in Ovarian Cancer Alter Repetitive Element Expression in a TP53-Dependent Manner.

Authors:  James I McDonald; Noor Diab; Elisa Arthofer; Melissa Hadley; Tomas Kanholm; Uzma Rentia; Stephanie Gomez; Angela Yu; Erin E Grundy; Olivia Cox; Michael J Topper; Xiaoyun Xing; Pamela L Strissel; Reiner Strick; Ting Wang; Stephen B Baylin; Katherine B Chiappinelli
Journal:  Cancer Res       Date:  2021-08-25       Impact factor: 12.701

5.  Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma.

Authors:  Lewis Au; Emine Hatipoglu; Marc Robert de Massy; Kevin Litchfield; Gordon Beattie; Andrew Rowan; Desiree Schnidrig; Rachael Thompson; Fiona Byrne; Stuart Horswell; Nicos Fotiadis; Steve Hazell; David Nicol; Scott T C Shepherd; Annika Fendler; Robert Mason; Lyra Del Rosario; Kim Edmonds; Karla Lingard; Sarah Sarker; Mary Mangwende; Eleanor Carlyle; Jan Attig; Kroopa Joshi; Imran Uddin; Pablo D Becker; Mariana Werner Sunderland; Ayse Akarca; Ignazio Puccio; William W Yang; Tom Lund; Kim Dhillon; Marcos Duran Vasquez; Ehsan Ghorani; Hang Xu; Charlotte Spencer; José I López; Anna Green; Ula Mahadeva; Elaine Borg; Miriam Mitchison; David A Moore; Ian Proctor; Mary Falzon; Lisa Pickering; Andrew J S Furness; James L Reading; Roberto Salgado; Teresa Marafioti; Mariam Jamal-Hanjani; George Kassiotis; Benny Chain; James Larkin; Charles Swanton; Sergio A Quezada; Samra Turajlic
Journal:  Cancer Cell       Date:  2021-10-28       Impact factor: 31.743

6.  Tumor neoantigenicity assessment with CSiN score incorporates clonality and immunogenicity to predict immunotherapy outcomes.

Authors:  Tianshi Lu; Shidan Wang; Lin Xu; Qinbo Zhou; Nirmish Singla; Jianjun Gao; Subrata Manna; Laurentiu Pop; Zhiqun Xie; Mingyi Chen; Jason J Luke; James Brugarolas; Raquibul Hannan; Tao Wang
Journal:  Sci Immunol       Date:  2020-02-21

Review 7.  Alternative tumour-specific antigens.

Authors:  Christof C Smith; Sara R Selitsky; Shengjie Chai; Paul M Armistead; Benjamin G Vincent; Jonathan S Serody
Journal:  Nat Rev Cancer       Date:  2019-07-05       Impact factor: 60.716

Review 8.  Beyond conventional immune-checkpoint inhibition - novel immunotherapies for renal cell carcinoma.

Authors:  David A Braun; Ziad Bakouny; Laure Hirsch; Ronan Flippot; Eliezer M Van Allen; Catherine J Wu; Toni K Choueiri
Journal:  Nat Rev Clin Oncol       Date:  2021-01-12       Impact factor: 66.675

Review 9.  Endogenous retroviruses in the origins and treatment of cancer.

Authors:  Natasha Jansz; Geoffrey J Faulkner
Journal:  Genome Biol       Date:  2021-05-10       Impact factor: 13.583

10.  Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma.

Authors:  Miriam Ficial; Opeyemi A Jegede; Miriam Sant'Angelo; Yue Hou; Abdallah Flaifel; Jean-Christophe Pignon; David A Braun; Megan Wind-Rotolo; Maura A Sticco-Ivins; Paul J Catalano; Gordon J Freeman; Arlene H Sharpe; F Stephen Hodi; Robert J Motzer; Catherine J Wu; Michael B Atkins; David F McDermott; Sachet A Shukla; Toni K Choueiri; Sabina Signoretti
Journal:  Clin Cancer Res       Date:  2020-11-20       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.